NO309090B1 - Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem - Google Patents

Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem Download PDF

Info

Publication number: NO309090B1
Authority: NO; Norway
Prior art keywords: formula; compound; pyrrolidin; acid; preparation
Prior art date: 1995-06-07

Application number

NO962360A

Other languages

English (en)

Norwegian (no)

Other versions

NO962360D0 (no

NO962360L (no

Inventor

Gilbert Lavielle

Olivier Muller

Mark Millan

Valerie Audinot

Original Assignee

Adir

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-06

Publication date

2000-12-11

1996-06-06 Application filed by Adir filed Critical Adir

1996-06-06 Publication of NO962360D0 publication Critical patent/NO962360D0/no

1996-12-09 Publication of NO962360L publication Critical patent/NO962360L/no

2000-12-11 Publication of NO309090B1 publication Critical patent/NO309090B1/no

Links

238000000034 method Methods 0.000 title claims description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title claims description 6
150000002475 indoles Chemical class 0.000 title description 4
150000003839 salts Chemical class 0.000 claims abstract description 9
239000002253 acid Substances 0.000 claims abstract description 5
125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 50
201000000980 schizophrenia Diseases 0.000 claims description 7
239000007858 starting material Substances 0.000 claims description 6
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 claims description 6
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
150000001412 amines Chemical class 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
238000000926 separation method Methods 0.000 claims description 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
238000000746 purification Methods 0.000 claims 1
-1 3-benzoylmethyl-pyrrolidin-1-yl Chemical group 0.000 abstract description 9
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 4
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 2
125000000217 alkyl group Chemical group 0.000 abstract 3
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
125000004953 trihalomethyl group Chemical group 0.000 abstract 2
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 20
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
238000004452 microanalysis Methods 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
229960003878 haloperidol Drugs 0.000 description 10
238000012360 testing method Methods 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 9
229960004170 clozapine Drugs 0.000 description 9
239000000243 solution Substances 0.000 description 9
108020003175 receptors Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
239000002904 solvent Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 7
208000009132 Catalepsy Diseases 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
206010047853 Waxy flexibility Diseases 0.000 description 6
239000000203 mixture Substances 0.000 description 6
ICNPOTSVAWPXRY-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-pyrrolidin-3-ylethanone Chemical compound C1=CC(F)=CC=C1C(=O)CC1CNCC1 ICNPOTSVAWPXRY-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000000561 anti-psychotic effect Effects 0.000 description 4
FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
238000011160 research Methods 0.000 description 4
YLMRHBWFHJJKKX-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[3-(5-methoxy-1H-indol-3-yl)propyl]pyrrolidin-3-yl]ethanone hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2NC=C1CCCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 YLMRHBWFHJJKKX-UHFFFAOYSA-N 0.000 description 3
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
101150013372 Htr2c gene Proteins 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
229960004046 apomorphine Drugs 0.000 description 3
230000001484 cataleptigenic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 2
XHCPPKSASMWCFC-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[2-(5-methoxy-1h-indol-3-yl)ethyl]pyrrolidin-3-yl]ethanone;hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2NC=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 XHCPPKSASMWCFC-UHFFFAOYSA-N 0.000 description 2
WNOKNPQVKXNVFV-UHFFFAOYSA-N 3-(5-methoxy-1h-indol-3-yl)propan-1-ol Chemical compound COC1=CC=C2NC=C(CCCO)C2=C1 WNOKNPQVKXNVFV-UHFFFAOYSA-N 0.000 description 2
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 2
COCNDHOPIHDTHK-UHFFFAOYSA-N 5-methoxyindole-3-acetic acid Chemical compound COC1=CC=C2NC=C(CC(O)=O)C2=C1 COCNDHOPIHDTHK-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
QJPOEAGOSMSFDO-UHFFFAOYSA-N Cl.C12=CC(OC)=CC=C2N(C)C=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 Chemical compound Cl.C12=CC(OC)=CC=C2N(C)C=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 QJPOEAGOSMSFDO-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000027776 Extrapyramidal disease Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
101150104779 HTR2A gene Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
229940054051 antipsychotic indole derivative Drugs 0.000 description 2
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000003480 eluent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
230000006698 induction Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000000698 schizophrenic effect Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
BDRZTSIMFCSLGA-UHFFFAOYSA-N (4-fluorophenyl)-[1-[3-(5-methoxy-1H-indol-3-yl)propyl]piperidin-4-yl]methanone hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2NC=C1CCCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 BDRZTSIMFCSLGA-UHFFFAOYSA-N 0.000 description 1
FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
DFFDCZLGTYJKKJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[2-(5-methoxy-1-methylindol-3-yl)ethyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2N(C)C=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 DFFDCZLGTYJKKJ-UHFFFAOYSA-N 0.000 description 1
KYJIQQZJLSVFGW-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[2-(5-methoxy-1h-indol-3-yl)ethyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2NC=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 KYJIQQZJLSVFGW-UHFFFAOYSA-N 0.000 description 1
WCNJIZGUBYGBKT-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[3-(5-methoxy-1-methylindol-3-yl)propyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2N(C)C=C1CCCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 WCNJIZGUBYGBKT-UHFFFAOYSA-N 0.000 description 1
ZRQATMNXTKBEOI-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[3-(5-methoxy-1h-indol-3-yl)propyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2NC=C1CCCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 ZRQATMNXTKBEOI-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
HASQSJVUSICPPG-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)ethanol Chemical compound COC1=CC=C2N(C)C=C(CCO)C2=C1 HASQSJVUSICPPG-UHFFFAOYSA-N 0.000 description 1
JQYYUWHWGCJWTN-UHFFFAOYSA-N 2-ethoxyoxolane Chemical compound CCOC1CCCO1 JQYYUWHWGCJWTN-UHFFFAOYSA-N 0.000 description 1
XTDKZSUYCXHXJM-UHFFFAOYSA-N 2-methoxyoxane Chemical compound COC1CCCCO1 XTDKZSUYCXHXJM-UHFFFAOYSA-N 0.000 description 1
OKAMTPRCXVGTND-UHFFFAOYSA-N 2-methoxyoxolane Chemical compound COC1CCCO1 OKAMTPRCXVGTND-UHFFFAOYSA-N 0.000 description 1
XBSJNZDZMZGLBF-UHFFFAOYSA-N 3-(3-bromopropyl)-5-methoxy-1-methylindole Chemical compound COC1=CC=C2N(C)C=C(CCCBr)C2=C1 XBSJNZDZMZGLBF-UHFFFAOYSA-N 0.000 description 1
AGRBFVDKFBYUNR-UHFFFAOYSA-N 3-(3-bromopropyl)-5-methoxy-1h-indole Chemical compound COC1=CC=C2NC=C(CCCBr)C2=C1 AGRBFVDKFBYUNR-UHFFFAOYSA-N 0.000 description 1
SUJRVGZNRZQMLS-UHFFFAOYSA-N 3-(5-methoxy-1-methylindol-3-yl)propan-1-ol Chemical compound COC1=CC=C2N(C)C=C(CCCO)C2=C1 SUJRVGZNRZQMLS-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QLWKTGDEPLRFAT-UHFFFAOYSA-N 5-Methoxytryptophol Chemical compound COC1=CC=C2NC=C(CCO)C2=C1 QLWKTGDEPLRFAT-UHFFFAOYSA-N 0.000 description 1
UKHRGUWGMSYUFE-UHFFFAOYSA-N 6-fluoro-3-(pyrrolidin-3-ylmethyl)-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1CC1CCNC1 UKHRGUWGMSYUFE-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
241000819038 Chichester Species 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000006136 alcoholysis reaction Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
150000008316 benzisoxazoles Chemical class 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
150000002473 indoazoles Chemical class 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
HHUXMVSOOZIODW-UHFFFAOYSA-N methyl 2-(5-methoxy-1-methylindol-3-yl)acetate Chemical compound C1=C(OC)C=C2C(CC(=O)OC)=CN(C)C2=C1 HHUXMVSOOZIODW-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940067157 phenylhydrazine Drugs 0.000 description 1
150000004031 phenylhydrazines Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
108010085082 sigma receptors Proteins 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Indole Compounds (AREA)

NO962360A 1995-06-07 1996-06-06 Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem NO309090B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9506663A FR2735129B1 (fr)	1995-06-07	1995-06-07	Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO962360D0 NO962360D0 (no)	1996-06-06
NO962360L NO962360L (no)	1996-12-09
NO309090B1 true NO309090B1 (no)	2000-12-11

Family

ID=9479672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO962360A NO309090B1 (no)	1995-06-07	1996-06-06	Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem

Country Status (15)

Country	Link
US (1)	US5703070A (de)
EP (1)	EP0747379B1 (de)
JP (1)	JPH08333362A (de)
CN (1)	CN1060772C (de)
AT (1)	ATE183183T1 (de)
AU (1)	AU702285B2 (de)
CA (1)	CA2178302C (de)
DE (1)	DE69603667T2 (de)
DK (1)	DK0747379T3 (de)
ES (1)	ES2137638T3 (de)
FR (1)	FR2735129B1 (de)
GR (1)	GR3031051T3 (de)
NO (1)	NO309090B1 (de)
NZ (1)	NZ286756A (de)
ZA (1)	ZA964842B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6187774B1 (en) *	1996-03-04	2001-02-13	Yoshitomi Pharmaceutical Industries, Ltd.	Fused heterocyclic compounds and pharmaceutical applications thereof
GB9718712D0 (en)	1997-09-03	1997-11-12	Merck Sharp & Dohme	Theraputic Agents
GB9718833D0 (en)	1997-09-04	1997-11-12	Merck Sharp & Dohme	Therapeutic agents
GB9805716D0 (en) *	1998-03-17	1998-05-13	Merck Sharp & Dohme	Therapeutic agents
GB9815317D0 (en) *	1998-07-15	1998-09-16	Merck Sharp & Dohme	Therapeutic agents
GB9816263D0 (en) *	1998-07-24	1998-09-23	Merck Sharp & Dohme	Therapeutic agents
AR028385A1 (es)	2000-04-28	2003-05-07	Acadia Pharm Inc	Agonistas muscarinicos
AU2003248091A1 (en) *	2002-07-19	2004-02-09	Meiji Dairies Corporation	Indole derivatives and drugs containing the same
WO2009076404A1 (en) *	2007-12-10	2009-06-18	Epix Delaware, Inc.	Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
BRPI0820701A2 (pt)	2007-12-11	2015-06-16	Cytopathfinder Inc	Composto de carboxamida e seu uso como agonistas do receptor de quimiocina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2708913A1 (de) *	1976-03-04	1977-09-08	Hoechst Ag	Benzoylpiperidyalkyl-indole und verwandte verbindungen
JPH0615529B2 (ja) *	1985-04-01	1994-03-02	エーザイ株式会社	新規ピペリジン誘導体
US5030639A (en) *	1987-07-13	1991-07-09	Hoechst-Roussel Pharmaceuticals Inc.	N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
US4980365A (en) *	1987-07-13	1990-12-25	Hoechst-Roussel Pharmaceuticals Inc.	N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
FR2644786B1 (fr) *	1989-03-21	1993-12-31	Adir Cie	Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2654104B1 (fr) *	1989-11-07	1992-01-03	Adir	Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5145845A (en) *	1991-05-14	1992-09-08	Warner-Lambert Co.	Substituted 2-carboxylindoles having pharmaceutical activity
FR2701026B1 (fr) *	1993-02-02	1995-03-31	Adir	Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2716680B1 (fr) *	1994-02-25	1996-04-05	Adir	Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

1995
- 1995-06-07 FR FR9506663A patent/FR2735129B1/fr not_active Expired - Fee Related
1996
- 1996-06-04 JP JP8141436A patent/JPH08333362A/ja active Pending
- 1996-06-05 CN CN96107985A patent/CN1060772C/zh not_active Expired - Fee Related
- 1996-06-05 AU AU54735/96A patent/AU702285B2/en not_active Ceased
- 1996-06-05 CA CA002178302A patent/CA2178302C/fr not_active Expired - Fee Related
- 1996-06-06 AT AT96401208T patent/ATE183183T1/de not_active IP Right Cessation
- 1996-06-06 DE DE69603667T patent/DE69603667T2/de not_active Expired - Fee Related
- 1996-06-06 US US08/663,464 patent/US5703070A/en not_active Expired - Fee Related
- 1996-06-06 NO NO962360A patent/NO309090B1/no not_active IP Right Cessation
- 1996-06-06 DK DK96401208T patent/DK0747379T3/da active
- 1996-06-06 NZ NZ286756A patent/NZ286756A/xx unknown
- 1996-06-06 ES ES96401208T patent/ES2137638T3/es not_active Expired - Lifetime
- 1996-06-06 EP EP96401208A patent/EP0747379B1/de not_active Expired - Lifetime
- 1996-06-07 ZA ZA964842A patent/ZA964842B/xx unknown
1999
- 1999-08-20 GR GR990402129T patent/GR3031051T3/el unknown

Also Published As

Publication number	Publication date
NO962360D0 (no)	1996-06-06
FR2735129B1 (fr)	1997-07-11
EP0747379A1 (de)	1996-12-11
DK0747379T3 (da)	2000-01-31
NZ286756A (en)	1997-08-22
ES2137638T3 (es)	1999-12-16
JPH08333362A (ja)	1996-12-17
EP0747379B1 (de)	1999-08-11
AU702285B2 (en)	1999-02-18
CN1143642A (zh)	1997-02-26
AU5473596A (en)	1996-12-19
US5703070A (en)	1997-12-30
DE69603667T2 (de)	2000-03-09
CA2178302C (fr)	2002-02-26
CN1060772C (zh)	2001-01-17
ATE183183T1 (de)	1999-08-15
DE69603667D1 (de)	1999-09-16
CA2178302A1 (fr)	1996-12-08
GR3031051T3 (en)	1999-12-31
NO962360L (no)	1996-12-09
ZA964842B (en)	1997-01-07
FR2735129A1 (fr)	1996-12-13

Legal Events

Date	Code	Title	Description
2005-04-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
CA2207835C (fr)	2001-10-02	Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP0745598B1 (de)	2001-08-22	Piperazin-, Piperidin- und 1,2,5,6-Tetrahydropyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DK174161B1 (da)	2002-07-29	Anellerede indolderivater, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af farmaceutisk præparat indeholdende dem
JPH03188077A (ja)	1991-08-16	新規なベンズイソキサゾール誘導体及び該誘導体を含有する製剤組成物
SK2492002A3 (en)	2002-09-10	Phenylpiperazine derivatives, process for their preparation and pharmaceutical composition comprising the same
NO309090B1 (no)	2000-12-11	Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
US5665722A (en)	1997-09-09	Benzofuran derivatives as D4 receptor antagonists
KR100603896B1 (ko)	2006-07-25	테트라하이드로 감마-카르볼린
JP2959987B2 (ja)	1999-10-06	新規なベンゾジオキサン化合物、それらの製造方法およびそれらを含有する医薬組成物
DE69829317T2 (de)	2006-04-06	Tetrahydrobenzindol-derivate
Schaus et al.	1990	Aporphines as antagonists of dopamine D-1 receptors
FR2731708A1 (fr)	1996-09-20	Derives de piperidine, leur procede de preparation et leur application en therapeutique
HU204517B (en)	1992-01-28	Process for producing new 1,4-benzoxazine derivatives and pharmaceutical compositions containing them
WO1997032848A1 (en)	1997-09-12	Fused heterocyclic compounds and pharmaceutical applications thereof
EP2907806A1 (de)	2015-08-19	Neue Verbindungen als selektive PDE4D Inhibitoren
ZA200304267B (en)	2004-08-30	8-{4-[3-(5-Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl]-2-methyl-4H-benzo[1,4]oxazin-3-onmesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site.
HU191086B (en)	1987-01-28	Process for preparing 1-/3-/6-fluoro-1,2benzisoxazol-3-yl/-propyl/-4-hydroxy-4-phenyl-piperidines
EP0765323B1 (de)	2001-07-11	4-(6-fluor-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-on-derivate,ihre herstellung und ihre verwendung in der behandlung von psychosen, schizophrenie und angstzuständen
FI63578B (fi)	1983-03-31	Analogifoerfarande foer framstaellning av nya farmakologiskt verksamma 1,3,4,14b-tetrahydro-2h,10h-pyrazino(1,2-a)pyrrolo(2,1-c)(1,4)bensodiazepiner
EP1192152A1 (de)	2002-04-03	Fluorierte benzodioxan imidazolin derivate, deren herstellung und deren therapeutische verwendung
JP3185222B2 (ja)	2001-07-09	チオフェン化合物およびその医薬用途
Araźny et al.	2000	Enantioselective synthesis of (1R)-1-(hydroxymethyl)-2-acetyl-1, 2, 3, 4-tetrahydro-β-carboline from L-(+)-tartaric acid
SK2982000A3 (en)	2000-07-11	Piperidinylmethyloxazolidinone derivative, process for its preparation, use thereof and pharmaceutical composition containing the same
PL245933B1 (pl)	2024-11-04	(Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne
FR2738823A1 (fr)	1997-03-21	Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique